trending Market Intelligence /marketintelligence/en/news-insights/trending/ibaML3xlLKbJ1osNpjzSGw2 content esgSubNav
In This List

Roche agrees to acquire genetic code analysis enzyme from Codexis

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Blog

Infographic: The Big Picture 2023 Issuer & Investor Relations Outlook


Roche agrees to acquire genetic code analysis enzyme from Codexis

Roche Holding AG agreed to acquire worldwide rights of Codexis Inc.'s EvoT4, an enzyme that is used to analyze a patient's genetic code and how their cells express their genes as proteins.

EvoT4 was developed using Codexis' proprietary protein engineering platform CodeEvolver.

Redwood City, Calif.-based Codexis is a protein engineering company and develops proteins for manufacturing pharmaceuticals, fine chemicals and industrial enzymes.

Financial details of the agreement were not disclosed.